1. Home
  2. IXHL vs ANVS Comparison

IXHL vs ANVS Comparison

Compare IXHL & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$4.14

Market Cap

45.0M

Sector

N/A

ML Signal

HOLD

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$1.84

Market Cap

46.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IXHL
ANVS
Founded
2001
2008
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.0M
46.5M
IPO Year
2024
2019

Fundamental Metrics

Financial Performance
Metric
IXHL
ANVS
Price
$4.14
$1.84
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
502.4K
1.2M
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.39
EPS
N/A
N/A
Revenue
$12,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$1.36
52 Week High
$6.39
$5.50

Technical Indicators

Market Signals
Indicator
IXHL
ANVS
Relative Strength Index (RSI) 66.02 40.47
Support Level $0.34 $1.56
Resistance Level $5.17 $2.67
Average True Range (ATR) 0.32 0.17
MACD 0.06 0.01
Stochastic Oscillator 91.82 23.13

Price Performance

Historical Comparison
IXHL
ANVS

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

About ANVS Annovis Bio Inc.

Annovis Bio Inc is a late-stage clinical drug platform company addressing neurodegeneration, including Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is developing its product candidate, buntanetap, a synthetically produced, orally administered, brain-penetrant small molecule designed to treat AD, PD, and potentially other chronic neurodegenerative diseases by inhibiting the synthesis of neurotoxic proteins and TDP43, which contribute to neurodegeneration and reduced axonal transport. Its pipeline includes buntanetap for chronic neurodegeneration, including AD, PD, and PDD, as well as in certain combination therapies, ANVS405 for acute neurodegeneration, and ANVS301 for AD.

Share on Social Networks: